Filings monitor · AMGN

What AMGEN INC's SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Capital Expenditures Program93 · importance in its document · 10-Q · 2026Q3
   Capital expenditures were $1.8 billion during the nine months ended September 30, 2026, compared with $1.2 billion in the same 2025 period. The spending primarily funded construction of new plants and manufacturing-capacity expansion.…
2. Prolia Biosimilar Competition84 · importance in its document · 10-Q · 2026Q3
   Prolia sales fell 45% globally in the third quarter and 37% in the first nine months of 2026 as multiple biosimilars launched in the U.S. and ROW. Nine-month sales declined to $2.118 billion from $3.360 billion. The quarterly decline…
3. Liquidity and Debt Position64 · importance in its document · 10-Q · 2026Q3
   At September 30, 2026, cash and cash equivalents were $13.190 billion, up from $9.129 billion at December 31, 2025; total assets were $96.048 billion. Current and long-term debt were $2.398 billion and $51.609 billion, respectively,…
4. Repatha Demand Growth64 · importance in its document · 10-Q · 2026Q3
   Global Repatha sales increased for the three and nine months ended September 30, 2026, primarily because of volume growth. Nine-month sales rose to $2.914 billion from $2.146 billion, an increase of approximately 36%. Sales increased in…
5. Liquidity and Cash Position64 · importance in its document · 8-K exhibit · 3 Nov 2026
   Cash and cash equivalents totaled $13.190 billion at September 30, 2026, compared with $9.445 billion at September 30, 2025. Cash increased by $4.061 billion over the first nine months of 2026, compared with a $2.528 billion decrease in…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

• Capital Expenditures ProgramImportance 93
  Capital expenditures were $1.8 billion during the nine months ended September 30, 2026, compared with $1.2 billion in the same 2025 period. The spending primarily funded construction of new plants and…
• Prolia Biosimilar CompetitionImportance 84 · +2 more on this subject
  Prolia sales fell 45% globally in the third quarter and 37% in the first nine months of 2026 as multiple biosimilars launched in the U.S. and ROW. Nine-month sales declined to $2.118 billion from $3.360 billion. The…
• Liquidity and Debt PositionImportance 64
  At September 30, 2026, cash and cash equivalents were $13.190 billion, up from $9.129 billion at December 31, 2025; total assets were $96.048 billion. Current and long-term debt were $2.398 billion and $51.609 billion,…
• Repatha Demand GrowthImportance 64 · +1 more on this subject
  Global Repatha sales increased for the three and nine months ended September 30, 2026, primarily because of volume growth. Nine-month sales rose to $2.914 billion from $2.146 billion, an increase of approximately 36%.…
• Operating Expense TrendsImportance 60
  Research and development expense increased 11% to $2.111 billion for the three months ended September 30, 2026, and increased 11% to $5.698 billion for the nine months. Quarterly R&D growth reflected higher Research…
• Operating Cash Flow TrendsImportance 59
  Net cash provided by operating activities increased to $10.432 billion for the nine months ended September 30, 2026, from $8.355 billion in the prior-year period. The increase primarily reflected the final $1.8 billion…
• Medicare Drug Price SettingImportance 58
  In January 2025, the Centers for Medicare & Medicaid Services selected Otezla for Medicare price setting, applicable beginning January 1, 2027. Amgen says the earlier-than-anticipated selection reduced estimated future…
• Enbrel Pricing PressureImportance 56
  Enbrel’s nine-month sales declined 11% to $1.511 billion, primarily reflecting a 19% lower net selling price. Amgen attributed the lower price to the ongoing impact of U.S. Medicare Part D price setting effective in…
• IRS Tax DisputesImportance 50
  The IRS disputes the allocation of profits between Amgen entities in the United States and Puerto Rico for tax years 2010–2015, seeking approximately $3.6 billion and $5.1 billion in additional federal tax,…
• Revenue Performance and MixImportance 49
  Worldwide product sales for the three months ended September 30, 2026 rose 8% to $9.883 billion from $9.137 billion, and nine-month sales rose 7% to $27.638 billion from $25.781 billion. Repatha sales increased on…
• Operating Income and MarginsImportance 49
  Operating expenses were $6.655 billion for the third quarter of 2026, down 5% year over year, and $19.147 billion for the first nine months, down 7%. The company attributed the decreases to lower amortization expense…
• U.S. Tax Law ChangesImportance 47
  The United States enacted the One Big Beautiful Bill Act (OB3) on July 4, 2025, with most provisions effective January 1, 2026. The law modifies the international tax framework, and Amgen says its foreign earnings are…

8-K filings last 12 months

• Results, no stated guidance change3 Nov 2026 · 8-K Item 2.02 · Routine · rule score 10
  Read from the attached exhibit: Competition and Pricing Pressure · Liquidity and Cash Position · Guidance and Outlook
• Board change27 Oct 2026 · 8-K Item 5.02 · Routine · rule score 10
  “On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately.”
  Read from the attached exhibit: Management Changes
• Results (release not read)4 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Capital Expenditure Outlook · Free Cash Flow and Liquidity · Operating Cash Flow Trends
• CFO exit, planned succession19 May 2026 · 8-K Item 5.02 · Routine · rule score 40
  “Additional Information A copy of the press release announcing Mr. Griffith’s retirement, and the hiring of Mr. Dittrich, as Chief Financial Officer, is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in…”
  Read from the attached exhibit: Management Changes
• Results (release not read)30 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
• Other officer change22 Apr 2026 · 8-K Item 5.02 · Routine · rule score 15
  “On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.”
• New debt19 Feb 2026 · 8-K Item 1.01 · Routine · rule score 10
  “On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850%…”
• Results (release not read)3 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 5 Aug 2026
  Competition and Pricing Pressure · Capital Expenditures Program · Operating Income and Margins

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.